Low-grade systemic inflammation in subclinical hypothyroidism

Stela Vudu, Gouri Durga Krishna
{"title":"Low-grade systemic inflammation in subclinical hypothyroidism","authors":"Stela Vudu, Gouri Durga Krishna","doi":"10.52418/moldovan-med-j.65-1.22.09","DOIUrl":null,"url":null,"abstract":"Background: Hypothyroidism is the deficiency in the production of thyroid hormones to meet the requirements of peripheral tissues. Subclinical hypothyroidism (SCH) is defined biochemically as normal serum free thyroxin concentration in the presence of an elevated serum thyroid-stimulating hormone (TSH) concentration. SCH may be associated with low-grade systemic inflammation (increased high sensitivity-C reactive protein (hs-CRP), one possible explanation may be that TSH in adipocytes promotes the release of interleukin-6 (IL-6). Studies have confirmed inflammatory biomarkers like hs-CRP and IL-6 to be a predictor of cardiovascular (CV) events. However, the treatment of SCH remains subject to debate. Conclusions: It is increasingly evident that SCH has prognostic values and crucial clinical effects, which leads to the view of SCH not being a compensated biochemical change sensu strictu. Even a modest but consistent fluctuation in the circulating thyroid hormone levels can create a response from the human heart. Well-timed treatment should be considered as a precaution to avoid the unfavourable CV diseases. The inflammatory biomarkers, namely CRP and IL-6 are exceptionally robust markers of cardiovascular risk. Thus, using these biomarkers may be helpful in assessing the cardiovascular risk in patients with subclinical hypothyroidism.","PeriodicalId":32733,"journal":{"name":"The Moldovan Medical Journal","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Moldovan Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52418/moldovan-med-j.65-1.22.09","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Hypothyroidism is the deficiency in the production of thyroid hormones to meet the requirements of peripheral tissues. Subclinical hypothyroidism (SCH) is defined biochemically as normal serum free thyroxin concentration in the presence of an elevated serum thyroid-stimulating hormone (TSH) concentration. SCH may be associated with low-grade systemic inflammation (increased high sensitivity-C reactive protein (hs-CRP), one possible explanation may be that TSH in adipocytes promotes the release of interleukin-6 (IL-6). Studies have confirmed inflammatory biomarkers like hs-CRP and IL-6 to be a predictor of cardiovascular (CV) events. However, the treatment of SCH remains subject to debate. Conclusions: It is increasingly evident that SCH has prognostic values and crucial clinical effects, which leads to the view of SCH not being a compensated biochemical change sensu strictu. Even a modest but consistent fluctuation in the circulating thyroid hormone levels can create a response from the human heart. Well-timed treatment should be considered as a precaution to avoid the unfavourable CV diseases. The inflammatory biomarkers, namely CRP and IL-6 are exceptionally robust markers of cardiovascular risk. Thus, using these biomarkers may be helpful in assessing the cardiovascular risk in patients with subclinical hypothyroidism.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
亚临床甲状腺功能减退的低度全身性炎症
背景:甲状腺功能减退症是指甲状腺激素分泌不足,无法满足外周组织的需要。亚临床甲状腺功能减退症(SCH)被定义为在血清促甲状腺激素(TSH)浓度升高的情况下血清游离甲状腺素浓度正常。SCH可能与低度全身性炎症(高敏c反应蛋白(hs-CRP)增加)有关,一种可能的解释可能是脂肪细胞中的TSH促进白细胞介素-6 (IL-6)的释放。研究证实炎症生物标志物如hs-CRP和IL-6是心血管(CV)事件的预测因子。然而,对SCH的治疗仍然存在争议。结论:越来越多的证据表明,SCH具有预后价值和重要的临床作用,这使得SCH不是一种代偿性的严格意义上的生化变化。即使是循环中甲状腺激素水平的适度但持续的波动也会引起人体心脏的反应。应考虑及时治疗作为预防措施,以避免不利的心血管疾病。炎症生物标志物,即CRP和IL-6是心血管风险的异常强大的标志物。因此,使用这些生物标志物可能有助于评估亚临床甲状腺功能减退患者的心血管风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
审稿时长
12 weeks
期刊最新文献
The effectiveness of the tissue engineering in the obtaining of the biological materials from the extracellular matrix Influence of the cytoprotective drug meldonium on diastolic dysfunction of the myocardium Cephalalgic syndrome in autosomal dominant cerebral arteriopathy with subcortical infarctions and leucoencephalopathy Repair surgical techniques in degenerative cardiac valve disease Ang1 immunoexpression vs vascular profile in chorio-villous germinative status in early term compromised pregnancies
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1